Subgroup analyses indicated that lenvatinib clinical activity was maintained regardless of tumor status (with or without extrahepatic spread or portal vein invasion), type of underlying hepatitis [hepatitis B virus (HBV) or hepatitis C virus], receipt of previous chemotherapy, or alpha-fetoprotein levels (AFP; <200 ng/mL or ≥200 ng/mL; see Online Resource Table S2). The gene discussed is AFP; the disease is hepatitis A virus infection.